Hanmi Pharmaceutical “Weight problems remedy agent confirmed to be efficient in weight reduction”

[이데일리 나은경 기자] Hanmi Pharmaceutical (128940)The principle outcomes of non-clinical analysis on the following technology of triple agent weight problems remedy (LA-GLP / GIP / GCG, code identify ‘HM15275’) had been introduced at a well known diabetes convention. – world The brand new drug candidate is anticipated to have a weight reduction impact of greater than 25% whereas lowering muscle loss.

Hanmi Pharmaceutical participated within the ‘American Diabetes Affiliation (ADA 2024)’ which was held in Orlando, USA from the twenty first to the twenty fourth and introduced 4 non-clinical research outcomes confirming the effectiveness of fantastic weight reduction and completely different growth technique HM15275 as poster 25 The day was revealed.

Researchers on the Hanmi Prescription drugs R&D Middle clarify to attendees based mostly on a poster containing key analysis data HM15275, a triple-agent next-generation agent for the remedy of weight problems, on the American Diabetes Affiliation. (Photograph = Hanmi Pharmaceutical)

HM15275, which is provided with Hanmi’s subsequent technology ‘Acylation’ steady platform expertise, optimizes the exercise of every of the three receptors, together with glucagon-like peptide (GLP-1 ), gastric inhibitory peptide (GIP), and glucagon (GCG) It’s specialised within the remedy of weight problems and designed to be efficient within the remedy of varied metabolic illnesses.

At this ADA, Hanmi Pharmaceutical confirmed the potential of HM15275 to be the ‘greatest in school new drug in school’ within the subject of weight problems remedy based mostly on efficacy in comparison with the load loss impact of surgical remedy.

At the moment, the GLP-1 based mostly medicine have been confirmed to have a weight reduction impact of round 15-20% in weight problems remedy scientific trials, however they don’t obtain weight reduction on the stage of bariatric surgical procedure (bariatric surgical procedure ). 25-30%), there’s an unmet medical want that can not be reached.

Hanmi Pharmaceutical introduced the outcomes of a research confirming that repeated administration of HM15275 in an weight problems mannequin confirmed higher weight reduction effectiveness in high quality and amount than present remedies. This impact was discovered to be a mechanism of motion by dietary management and elevated power metabolism because of the superior triple pharmacological motion of HM15275.

The outcomes of three different non-clinical research revealed by Hanmi Pharmaceutical present that HM15275 is efficient in a number of metabolic illnesses in addition to its glorious weight reduction efficacy and mechanism of motion. Incretin-based medicine are increasing their subject of use past the remedy of diabetes and weight problems to varied therapeutic areas. Specifically, the indications for these medicine are growing as their effectiveness in growing cardiovascular and kidney illnesses is confirmed.

Hanmi Pharmaceutical has analysis outcomes that counsel that HM15275 could have a greater cardioprotective impact than present remedies within the signs of cardiac hypertrophy and cardiac fibrosis brought on by hypertension, and it has considerably enhance the decline in train capability that happens in a number of fashions of coronary heart failure, growing the flexibility to deal with coronary heart failure The confirmed outcomes had been introduced. As well as, by proving that it will probably have a direct therapeutic impact on cardiomyocytes and cardiac fibroblasts, it has been confirmed that it will probably enhance cardiovascular illnesses past the constructive results by improved metabolism.

In one other presentation, outcomes had been revealed exhibiting the efficacy of HM15275 in enhancing kidney perform and fibrosis in a number of kidney illness fashions, based mostly on the truth that HM15275 can act immediately on podocytes and renal tubular epithelial cells that performs filtering capabilities within the kidney.

Hanmi Pharmaceutical obtained approval for a section 1 scientific trial (IND) for HM15275 from the US Meals and Drug Administration (FDA) final Might, it started enrolling sufferers who participated within the HM15275 scientific trial in the course of this month, and completed the primary dose. .

Choi In-young, head of Hanmi Prescription drugs R&D Middle, mentioned, “This yr’s ADA announcement has particular significance because it solidified our main place within the subject of weight problems remedy by introducing the ‘weight problems drug’ the following technology’ for the primary time. at a world tutorial convention.